Author: admin

DelveInsight’s “Immune Complex Membranoproliferative Glomerulonephritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Immune Complex Membranoproliferative Glomerulonephritis, historical and forecasted epidemiology as well as the Immune Complex Membranoproliferative Glomerulonephritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Immune Complex Membranoproliferative Glomerulonephritis, offering comprehensive insights into the Immune Complex Membranoproliferative Glomerulonephritis revenue trends, prevalence, and treatment landscape. The report delves into key Immune Complex Membranoproliferative Glomerulonephritis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Immune Complex Membranoproliferative Glomerulonephritis therapies. Additionally, we cover the landscape of Immune Complex Membranoproliferative Glomerulonephritis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Immune Complex Membranoproliferative Glomerulonephritis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Immune Complex Membranoproliferative Glomerulonephritis space.

To Know in detail about the Immune Complex Membranoproliferative Glomerulonephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Immune Complex Membranoproliferative Glomerulonephritis Market Forecast

Some of the key facts of the Immune Complex Membranoproliferative Glomerulonephritis Market Report:

• The Immune Complex Membranoproliferative Glomerulonephritis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• The IC-MPGN market in the United States was valued at approximately USD 12 million in 2023 and is projected to grow by 2034, driven by a rise in diagnosed cases and the introduction of emerging therapies with premium pricing.

• Key Immune Complex Membranoproliferative Glomerulonephritis Companies: Novartis, Apellis Pharmaceuticals, and others.

• Key Immune Complex Membranoproliferative Glomerulonephritis Therapies: Iptacopan (LNP023), Pegcetacoplan (APL-2), and others

• The Immune Complex Membranoproliferative Glomerulonephritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Immune Complex Membranoproliferative Glomerulonephritis pipeline products will significantly revolutionize the Immune Complex Membranoproliferative Glomerulonephritis market dynamics.

• In 2023, the total diagnosed prevalent population of IC-MPGN across the 7MM was estimated to be around 7,000.

• In 2023, the diagnosed prevalent population of IC-MPGN in the United States was estimated to be around 3,770.

• In 2023, Germany had the highest diagnosed prevalent population of IC-MPGN in the EU4 and the UK, followed by Spain, with Italy reporting the fewest cases.

Immune Complex Membranoproliferative Glomerulonephritis Overview

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a type of kidney disorder characterized by inflammation and changes in the kidney’s glomeruli, the tiny filtering units. It occurs when immune complexes, which are formed by antibodies and antigens, accumulate in the kidneys and trigger an immune response, leading to damage. This condition can result in symptoms such as proteinuria (excessive protein in the urine), hematuria (blood in the urine), swelling, and impaired kidney function. IC-MPGN can be caused by infections, autoimmune diseases, or certain cancers, and treatment typically focuses on addressing the underlying cause and managing symptoms to prevent kidney damage.

Get a Free sample for the Immune Complex Membranoproliferative Glomerulonephritis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 202 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation:

The Immune Complex Membranoproliferative Glomerulonephritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Immune Complex Membranoproliferative Glomerulonephritis

• Prevalent Cases of Immune Complex Membranoproliferative Glomerulonephritis by severity

• Gender-specific Prevalence of Immune Complex Membranoproliferative Glomerulonephritis

• Diagnosed Cases of Episodic and Chronic Immune Complex Membranoproliferative Glomerulonephritis

Download the report to understand which factors are driving Immune Complex Membranoproliferative Glomerulonephritis epidemiology trends @ Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Forecast

Immune Complex Membranoproliferative Glomerulonephritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Complex Membranoproliferative Glomerulonephritis market or expected to get launched during the study period. The analysis covers Immune Complex Membranoproliferative Glomerulonephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Immune Complex Membranoproliferative Glomerulonephritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Immune Complex Membranoproliferative Glomerulonephritis Therapies and Key Companies

• Iptacopan (LNP023): Novartis Pharmaceuticals

• Pegcetacoplan (APL-2): Apellis Pharmaceuticals

Discover more about therapies set to grab major Immune Complex Membranoproliferative Glomerulonephritis market share @ Immune Complex Membranoproliferative Glomerulonephritis Treatment Landscape

Immune Complex Membranoproliferative Glomerulonephritis Market Drivers

• Increasing Prevalence

• Emerging Therapies

• Aging Population

• Advances in Immunology

• Improved Diagnostics

• Research & Development Investment

Immune Complex Membranoproliferative Glomerulonephritis Market Barriers

• Limited Treatment Options

• Complex Disease Pathogenesis

• Small Patient Population

• Lack of Awareness

• Regulatory Challenges

Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Immune Complex Membranoproliferative Glomerulonephritis Companies: Novartis, Apellis Pharmaceuticals, and others

• Key Immune Complex Membranoproliferative Glomerulonephritis Therapies: Iptacopan (LNP023), Pegcetacoplan (APL-2), and others

• Immune Complex Membranoproliferative Glomerulonephritis Therapeutic Assessment: Immune Complex Membranoproliferative Glomerulonephritis current marketed and Immune Complex Membranoproliferative Glomerulonephritis emerging therapies

• Immune Complex Membranoproliferative Glomerulonephritis Market Dynamics: Immune Complex Membranoproliferative Glomerulonephritis market drivers and Immune Complex Membranoproliferative Glomerulonephritis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs, KOL’s views, Analyst’s views, Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement

To know more about Immune Complex Membranoproliferative Glomerulonephritis companies working in the treatment market, visit @ Immune Complex Membranoproliferative Glomerulonephritis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Immune Complex Membranoproliferative Glomerulonephritis Market Report Introduction

2. Executive Summary for Immune Complex Membranoproliferative Glomerulonephritis

3. SWOT analysis of Immune Complex Membranoproliferative Glomerulonephritis

4. Immune Complex Membranoproliferative Glomerulonephritis Patient Share (%) Overview at a Glance

5. Immune Complex Membranoproliferative Glomerulonephritis Market Overview at a Glance

6. Immune Complex Membranoproliferative Glomerulonephritis Disease Background and Overview

7. Immune Complex Membranoproliferative Glomerulonephritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Immune Complex Membranoproliferative Glomerulonephritis

9. Immune Complex Membranoproliferative Glomerulonephritis Current Treatment and Medical Practices

10. Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs

11. Immune Complex Membranoproliferative Glomerulonephritis Emerging Therapies

12. Immune Complex Membranoproliferative Glomerulonephritis Market Outlook

13. Country-Wise Immune Complex Membranoproliferative Glomerulonephritis Market Analysis (2020–2034)

14. Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement of Therapies

15. Immune Complex Membranoproliferative Glomerulonephritis Market Drivers

16. Immune Complex Membranoproliferative Glomerulonephritis Market Barriers

17. Immune Complex Membranoproliferative Glomerulonephritis Appendix

18. Immune Complex Membranoproliferative Glomerulonephritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IC-MPGN Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Novartis, Apellis Pharmaceuticals

“Short Bowel Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Short Bowel Syndrome Market.

The Short Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Short Bowel Syndrome Pipeline Report:

• Companies across the globe are diligently working toward developing novel Short Bowel Syndrome treatment therapies with a considerable amount of success over the years.

• Short Bowel Syndrome companies working in the treatment market are Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others, are developing therapies for the Short Bowel Syndrome treatment

• Emerging Short Bowel Syndrome therapies in the different phases of clinical trials are- Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others are expected to have a significant impact on the Short Bowel Syndrome market in the coming years.

• In October 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company focused on gastrointestinal healthcare, will present new results at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The findings come from subgroup analyses of the primary endpoint in the pivotal Phase III STARS trial, assessing apraglutide’s treatment effect in adults with short bowel syndrome with intestinal failure (SBS-IF). The data, which will be shared in an oral presentation on October 29 from 8:30 am – 8:40 am ET, show that apraglutide demonstrated a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics, such as the length of remnant bowel. These results further support the previously reported positive data from the Phase III trial.

• In May 2024, Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary companies, Napo Pharmaceuticals and Napo Therapeutics, have submitted a Clinical Trial Application (CTA) to the health authorities in Italy and Germany to initiate a Phase 2 clinical trial for Jaguar’s novel plant-based prescription drug, crofelemer, for treating short bowel syndrome (SBS) with intestinal failure in adults. Additionally, Napo Therapeutics has submitted a CTA to AIFA, the Italian health authority, to conduct a clinical trial for pediatric patients with microvillus inclusion disease (MVID). The approval process for this trial is also underway in the United Arab Emirates with Dubai Health. The MVID clinical trial is being conducted under an active US Investigational New Drug (IND) application.

• In February 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has unveiled promising top-line outcomes from its pivotal Phase III STARS trial. This trial assessed the effectiveness and safety of subcutaneous apraglutide administered once weekly in reducing the dependency on parenteral support (PS) in adult patients diagnosed with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF is a rare and severe condition resulting in organ failure, where patients rely on PS. Approximately 18,000 adult patients in the United States, Europe, and Japan are affected by this condition. Following these findings, Ironwood intends to submit a new drug application (NDA) and other regulatory documents for apraglutide aimed at treating adult SBS patients reliant on PS.

Short Bowel Syndrome Overview

Short Bowel Syndrome (SBS) is a condition that occurs when a person has lost a significant portion of their small intestine, either due to surgery or disease. This results in the inability of the body to absorb enough nutrients and fluids from food. The severity of SBS depends on how much of the small intestine is removed and its ability to adapt. Symptoms include diarrhea, dehydration, malnutrition, and weight loss. SBS is typically managed through dietary changes, nutritional supplements, and in some cases, intravenous feeding or medications to improve nutrient absorption.

Get a Free Sample PDF Report to know more about Short Bowel Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/short-bowel-syndrome-pipeline-insight

Emerging Short Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:

• Glepaglutide: Zealand Pharma

• Apraglutide: Ironwood Pharmaceuticals

• HM15912: Hanmi Pharmaceutical

• Teduglutide: Shire

• Pancreatic Enzyme: AbbVie

• HM15912 Active: Hanmi Pharma

• Somatropin: EMD Serono

• ZP1848: Zealand Pharma

• FE203799: VectivBio AG

• Clinolipid: Baxter Healthcare

Short Bowel Syndrome Route of Administration

Short Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Short Bowel Syndrome Molecule Type

Short Bowel Syndrome Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Short Bowel Syndrome Pipeline Therapeutics Assessment

• Short Bowel Syndrome Assessment by Product Type

• Short Bowel Syndrome By Stage and Product Type

• Short Bowel Syndrome Assessment by Route of Administration

• Short Bowel Syndrome By Stage and Route of Administration

• Short Bowel Syndrome Assessment by Molecule Type

• Short Bowel Syndrome by Stage and Molecule Type

DelveInsight’s Short Bowel Syndrome Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Short Bowel Syndrome product details are provided in the report. Download the Short Bowel Syndrome pipeline report to learn more about the emerging Short Bowel Syndrome therapies

Some of the key companies in the Short Bowel Syndrome Therapeutics Market include:

Key companies developing therapies for Short Bowel Syndrome are – VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, Hanmi Pharm.Co., Ltd., and Pharmascience, Inc., and others.

Short Bowel Syndrome Pipeline Analysis:

The Short Bowel Syndrome pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Short Bowel Syndrome with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Short Bowel Syndrome Treatment.

• Short Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Short Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Short Bowel Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Short Bowel Syndrome drugs and therapies

Short Bowel Syndrome Pipeline Market Strengths

• In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.

• Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Short Bowel Syndrome Pipeline Market Opportunities

• Several organizations are actively working to provide information and increase awareness of such disorders.

• There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

Scope of Short Bowel Syndrome Pipeline Drug Insight

• Coverage: Global

• Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others

• Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others

• Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies

• Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers

Request for Sample PDF Report for Short Bowel Syndrome Pipeline Assessment and clinical trials

Table of Contents

1. Short Bowel Syndrome Report Introduction

2. Short Bowel Syndrome Executive Summary

3. Short Bowel Syndrome Overview

4. Short Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Short Bowel Syndrome Pipeline Therapeutics

6. Short Bowel Syndrome Late Stage Products (Phase II/III)

7. Short Bowel Syndrome Mid Stage Products (Phase II)

8. Short Bowel Syndrome Early Stage Products (Phase I)

9. Short Bowel Syndrome Preclinical Stage Products

10. Short Bowel Syndrome Therapeutics Assessment

11. Short Bowel Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Short Bowel Syndrome Key Companies

14. Short Bowel Syndrome Key Products

15. Short Bowel Syndrome Unmet Needs

16 . Short Bowel Syndrome Market Drivers and Barriers

17. Short Bowel Syndrome Future Perspectives and Conclusion

18. Short Bowel Syndrome Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Short Bowel Syndrome Pipeline Trends 2024: Clinical Trials, Analysis of Clinical Trials, Therapies, MOA, ROA, and Developments by DelveInsight | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire